ISPC vs. DKDCA, DYNT, CNSP, CMND, RSLS, WINT, AEMD, ACON, DRMA, and GLMD
Should you be buying iSpecimen stock or one of its competitors? The main competitors of iSpecimen include Data Knights Acquisition (DKDCA), Dynatronics (DYNT), CNS Pharmaceuticals (CNSP), Clearmind Medicine (CMND), ReShape Lifesciences (RSLS), Windtree Therapeutics (WINT), Aethlon Medical (AEMD), Aclarion (ACON), Dermata Therapeutics (DRMA), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "medical" sector.
Data Knights Acquisition (NASDAQ:DKDCA) and iSpecimen (NASDAQ:ISPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
Data Knights Acquisition has higher earnings, but lower revenue than iSpecimen. Data Knights Acquisition is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Data Knights Acquisition has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
iSpecimen received 3 more outperform votes than Data Knights Acquisition when rated by MarketBeat users.
35.3% of Data Knights Acquisition shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 45.7% of Data Knights Acquisition shares are held by insiders. Comparatively, 32.7% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Data Knights Acquisition and Data Knights Acquisition both had 1 articles in the media. Data Knights Acquisition's average media sentiment score of 1.29 beat iSpecimen's score of 0.00 indicating that iSpecimen is being referred to more favorably in the news media.
Data Knights Acquisition has a net margin of 0.00% compared to Data Knights Acquisition's net margin of -124.84%. iSpecimen's return on equity of 0.00% beat Data Knights Acquisition's return on equity.
Summary
Data Knights Acquisition beats iSpecimen on 7 of the 12 factors compared between the two stocks.
Get iSpecimen News Delivered to You Automatically
Sign up to receive the latest news and ratings for ISPC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ISPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iSpecimen Competitors List
Related Companies and Tools
